2002
DOI: 10.1046/j.1471-4159.2002.01146.x
|View full text |Cite
|
Sign up to set email alerts
|

Oligodendrocyte‐myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth

Abstract: A protein fraction purified from bovine brain myelin, previously called arretin because of its ability to inhibit neurite outgrowth, has been identified as consisting predominantly of oligodendrocyte-myelin glycoprotein (OMgp). We show that it is a potent inhibitor of neurite outgrowth from rat cerebellar granule and hippocampal cells; from dorsal root ganglion explants in which growth cone collapse was observed; from rat retinal ganglion neurons; and from NG108 and PC12 cells. OMgp purified by a different pro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
148
0

Year Published

2003
2003
2017
2017

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 241 publications
(150 citation statements)
references
References 21 publications
2
148
0
Order By: Relevance
“…These results are consistent with several earlier reports that integrin activation could enhance axon growth from neurons in vitro, even when cultured in the presence of inhibitory molecules such as amino-Nogo or aggrecan (Ivins et al, 2000;Lein et al, 2000;Hu and Strittmatter, 2008;Tan et al, 2011), and also with our demonstration that expression of a tenascin-binding integrin can promote axon regeneration (Andrews et al, 2009). CNS injuries cause an upregulation of myelin-related inhibitors (e.g., Nogo, oligodendrocyte myelin glycoprotein, myelin-associated glycoprotein) (McKerracher et al, 1994;Mukhopadhyay et al, 1994;GrandPré et al, 2000GrandPré et al, , 2002Prinjha et al, 2000;Kottis et al, 2002;Wang et al, 2002) and CSPGs (e.g., aggrecan, brevican, phosphacan, versican), which impair regenerative responses (Jaworski et al, 1999;McKeon et al, 1999;Asher et al, 2000;Afshari et al, 2010). Our experiment suggests that integrin activation might be a general method to overcome these inhibitory effects and promote axon regeneration in vivo.…”
Section: Differential Effects Of Kindlin-1 and -2supporting
confidence: 93%
“…These results are consistent with several earlier reports that integrin activation could enhance axon growth from neurons in vitro, even when cultured in the presence of inhibitory molecules such as amino-Nogo or aggrecan (Ivins et al, 2000;Lein et al, 2000;Hu and Strittmatter, 2008;Tan et al, 2011), and also with our demonstration that expression of a tenascin-binding integrin can promote axon regeneration (Andrews et al, 2009). CNS injuries cause an upregulation of myelin-related inhibitors (e.g., Nogo, oligodendrocyte myelin glycoprotein, myelin-associated glycoprotein) (McKerracher et al, 1994;Mukhopadhyay et al, 1994;GrandPré et al, 2000GrandPré et al, , 2002Prinjha et al, 2000;Kottis et al, 2002;Wang et al, 2002) and CSPGs (e.g., aggrecan, brevican, phosphacan, versican), which impair regenerative responses (Jaworski et al, 1999;McKeon et al, 1999;Asher et al, 2000;Afshari et al, 2010). Our experiment suggests that integrin activation might be a general method to overcome these inhibitory effects and promote axon regeneration in vivo.…”
Section: Differential Effects Of Kindlin-1 and -2supporting
confidence: 93%
“…Omgp contains a leucine-rich repeat (LRR) domain, followed by a C-terminal domain with serine/threonine repeats. In addition, Omgp is the protein that is responsible for the inhibition by the myelin fraction originally termed 'arretin' 31 . Like Mag and Nogo, Omgp induces growth cone collapse and inhibits neurite outgrowth.…”
Section: Box 1 | Regeneration In the Pns Versus The Cnsmentioning
confidence: 99%
“…Indeed, several components from the disrupted myelin and extracellular matrix components produced by reactive astrocytes, microglia, and fibrocytes show strong inhibitory properties on axonal outgrowth and regeneration, limiting the recovery of motor function after injury (Savio and Schwab, 1990;Schnell and Schwab, 1990;McKerracher et al, 1994;Bregman et al, 1995;Davies et al, 1999;Chen et al, 2000;Bradbury et al, 2002;GrandPré et al, 2002;Kottis et al, 2002;Sroga et al, 2003;Silver and Miller, 2004;Yiu and He, 2006;Hellal et al, 2011;Wang et al, 2011). In p53 Ϫ/Ϫ injured cords, aberrant glial proliferation is accompanied by enhanced glial scar formation, as shown by GFAP-and fibronectin-positive scar tissue revealing a bigger reactive astrocyte area around the lesion site and an enlarged lesion core.…”
Section: Discussionmentioning
confidence: 99%